The UK prime minister David Cameron has said he wants Britain to lead the way in the battle against antimicrobial resistance.
Growing numbers of bacterial and viral infections are resistant to antimicrobial drugs, but no new classes of antibiotics have come on the market for more than 25 years. Around 25,000 people already die each year from infections resistant to antibiotic drugs in Europe alone and the lack of new drugs which are capable of fighting bacteria has been described by the World Health Organization as one of the most significant global risks facing modern medicine.
Mr Cameron has commissioned an independent review, led by the internationally renowned economist Jim O’Neill and co-funded and hosted by the world’s second largest medical research foundation, the Wellcome Trust, to explore the economic issues surrounding antimicrobial resistance. The review will set out a plan for encouraging and accelerating the discovery and development of new generations of antibiotics, and will examine:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze